3 results
Primary: Safety and tolerability.Secondary: Clinical and endoscopic remission, symptomatic clinical remission, clinical response, mucosal healing, health related QoL, CRP, faecal calprotectin, pharmacokinetics.
Primary Study ObjectiveTo assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via registered intramuscular (IM) injection…
Primary Objective:Evaluating the predictive value of CAUS to assess the steatosis severity, combining multiple CAUS parameters (RAC, LAT, SNR, MU, AX), with 1H-MRS as a reference in adult patients with CIF.Secondary Objective(s):-To assess the…